Loxoprofen Sodium Dispersible Tablets

Loxoprofen sodium. Chemical name: 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate sodium dihydrate Molecular weight: C15H17NaO3·2H2O

This product is white or off-white tablets.

Oral administration: add this product to an appropriate amount of water, stir well and take. Do not take the medicine on an empty stomach: 1. For indications 1 and 2, adults take 60 mg (1 tablet) once, 3 times a day. For all-in-one administration, take 60 to 120 mg (1 to 2 tablets) once, and increase or decrease the dosage according to age and symptoms or follow the doctor's advice. 2. For indication 3, adults take 60 mg (1 tablet) once, and increase or decrease the dosage according to age and symptoms. It is recommended to take 60 mg twice a day, and the maximum daily dose should not exceed 180 mg (3 tablets) or follow the doctor's advice. In addition, do not take the medicine on an empty stomach.

According to foreign literature reports: (This item includes adverse reaction reports whose frequency cannot be calculated) Among the total 13,486 cases, there were 409 cases (3.03%) of adverse reaction reports. The main reports include digestive system symptoms (stomach and abdominal discomfort, stomach pain, nausea and vomiting, loss of appetite, etc. 2.25%), edema and swelling (0.59%), rash and urticaria (0.21%), drowsiness (0.10%), etc. (1) Major adverse reactions 1) Shock (unknown frequency): It may cause shock, so you should observe carefully. If abnormalities occur, stop the drug immediately and give appropriate treatment. 2) Hemolytic anemia (unknown frequency): Hemolytic anemia may occur, so blood tests should be performed and observe carefully. If abnormalities occur, stop the drug immediately and give appropriate treatment. 3) Mucocutaneous and ocular syndrome (unknown frequency)

1. Patients with known allergies to this product. 2. Patients who have asthma, urticaria or allergic reactions after taking aspirin or other non-steroidal anti-inflammatory drugs. 3. Contraindicated for the treatment of perioperative pain during coronary artery bypass grafting (CABG). 4. Patients with a history of gastrointestinal bleeding or perforation after the use of non-steroidal anti-inflammatory drugs. 5. Patients with active peptic ulcers/bleeding, or patients with recurrent ulcers/bleeding in the past. 6. Patients with severe heart failure.

Precautions for children: The safety of the drug for low birth weight infants, newborns, infants, young children or children has not been established. Therefore, it is not recommended for children. Precautions for pregnancy and lactation: 1. Pregnant women or women who may become pregnant can only be given the drug when the benefits of treatment outweigh the risks (the safety of the drug during pregnancy has not been established). 2. Animal tests on rats have reported delayed delivery. 3. In late pregnancy rat administration tests, there were reports of contraction of the fetal ductus arteriosus. Therefore, this product is contraindicated for women in late pregnancy. 4. Animal tests on rats have reported milk absorption, so breastfeeding women should avoid using the drug. Precautions for the elderly: Elderly patients are prone to adverse reactions, so the drug should be started at a low dose, and the patient's condition should be observed and the drug should be used with caution.

When this product is used in combination with the following drugs, the following drug interactions should be noted: Coumarin anticoagulants (warfarin, etc.) will enhance the anticoagulant effect of this drug, so please note that the dosage should be reduced when necessary. Because this product inhibits the biosynthesis of prostaglandins, it inhibits platelet aggregation and reduces blood coagulation, which has an additive effect on the anticoagulant effect of this drug. Sulfonylurea hypoglycemic drugs (tolbutamide, etc.) will enhance the hypoglycemic effect of this drug, so please note that the dosage should be reduced when necessary. The protein binding rate of this product in the human body is 97.0% for loxoprofen sodium and 92.8% for the trans-OH body. Therefore, when used in combination with drugs with high protein binding rates, the active components of the combined drugs in the blood will increase, thereby increasing the effect of the drug.

Light-shielding and sealed.

60mg*24s

18 months

Shandong YUXIN Pharmaceutical Co., Ltd.

• Founded in:

  2010-12-30

• Address:

  West side of the middle section of Luoqi Road, Luozhuang District, Linyi City

• Tax NO.:

  91371300567713650P

• Registered Funds:

  800 million yuan

• Email:

  Log in to view